Breast cancer survivors
People with a genetic mutation linked to cancer risk
Women under 45
Women over 45
Other mutations: Women at high risk for breast cancer
The risk of breast cancer is exceptionally high in women who have a personal or family history of breast cancer or who carry a mutation in BRCA or certain other genes. More frequent screening is one strategy for early detection of breast cancer for these women. Study results presented at the 2017 San Antonio Breast Cancer Symposium suggest that MRI screening every 6 months may be more effective than the currently recommended annual breast MRI and annual mammogram in detecting early stage breast cancers-which are more treatable-in high-risk women. (2/1/18)
|At a glance||Questions for your doctor|
|Guidelines||Resources and references|
Whether women at high risk for breast cancer benefit from biannual breast
The National Comprehensive Cancer Network and the American Cancer Society recommend a screening breast MRI and a mammogram each year for high-risk women, typically starting at age 30. In studies of annual MRI, the cancer detection rates are quite variable. In most studies of annual MRI, only about half of the women in the study were diagnosed with small tumors (<1 cm) and some were diagnosed with lymph node positive tumors. Both the diagnosis of tumors larger than 1cm and lymph node positive tumors translates into more advanced stage disease.
Is the recommended screening regimen for high-risk women the best screening protocol? Questions remain, and many experts are concerned that the increased sensitivity of MRIs may result in false positives that require follow-up screening or biopsy, and increased psychosocial distress that may negatively impact a women’s quality of life. Three posters presented at the 2017 San Antonio Breast Cancer Symposium addressed these issues.
Between 2004 and 2016, researchers at the University of Chicago recruited high-risk women into a clinical trial to prospectively evaluate semiannual MRI and annual mammography. Eligible participants had a lifetime breast cancer risk greater than 20% and/or an inherited mutation in BRCA1, BRCA2, CDH1, PALB2, CHEK2 or other cancer susceptibility gene. (More than half of the enrolled women had a mutation in a high-risk gene.) The participants’ median age was 44 (ranging from 21-73).
The 295 enrolled women were given a clinical breast exam and an MRI scan every 6 months, and a digital mammogram every 12 months:
If you are at high risk for breast cancer, this study suggests that having an MRI every 6 months may more effectively detect early-stage breast cancer than an annual MRI and mammogram. In this study, the MRI cancer detection rates are comparable to previous studies looking at MRI. Where this study is unique and meaningful is that it was able to detect earlier stage cancers that are likely more curable and consequently may lead to improved survival in high-risk women.
This study also suggests that semiannual MRIs do not substantially increase recall or biopsy rates; nor do they increase anxiety or depression. This study also suggests that biannual MRI may be an especially effective screening tool for BRCA1 mutation carriers. The study’s lead author, Olufunmilayo Olopade, MD, professor of medicine and human genetics and director of the University of Chicago's Center for Clinical Cancer Genetics was quoted in the media articles, saying "Mammograms remain important for most women. But for women at high risk who are getting an MRI every six months, annual mammograms could probably be eliminated."
Screening breast MRIs for women are not without controversy. Guidelines recommend that they be given with a contrast agent—an intravenous substance that enhances MRI imaging and makes it easier to identify abnormalities. Most contrast agents used for MRI include gadolinium, a metal-based chemical. Experts have expressed concern about the safety of gadolinium, primarily because it remains in patients’ brains and bodies for months to years. Recently, the FDA required that labels for gadolinium-based contrast agents be updated to include a warning and safety measures that should be followed before the agents are given to patients. Please visit Breast Cancer Screening on the FORCE website for updated information on this new warning.
The National Comprehensive Cancer Network (NCCN) establishes guidelines for breast cancer screening and cancer care in the U.S. For women with increased risk (a lifetime risk for breast cancer of 20% or more), the guidelines recommend the following screening:
The following breast cancer screening clinical trials are currently enrolling participants:
Breast Cancer News
Women with a personal or family history of breast cancer or a mutation in BRCA1, BRCA2 or certain other genes have a higher-than-normal risk of breast cancer. An intensified screening regimen—annual MRI and annual mammogram–is currently recommended as an early detection strategy for these high-risk women. However, experts still have questions regarding the type and frequency of screening that is best for high-risk women.
Whether women at high risk for breast cancer benefit from biannual breast MRI screening.
Women enrolled in the study had mutations in one of 11 known breast cancer-related genes, a diagnosis of breast cancer or carcinoma in situ before age 35, or a mother or sister who was diagnosed with breast cancer before age 50 (before age 40 for African Americans). The mean age at participation was 43.3 years.
Participants had semiannual breast MRI and annual mammography. During the study, researchers performed 2,111 MRIs (averaging about 7 per participant) and 1,223 mammograms (4 per participant). Biopsy was recommended when mammography results were categorized as suspicious or highly suspicious. Further imaging was recommended and biopsy was performed if clinically indicated when MRI results were incomplete and mammography was suspicious or highly suspicious. Patients also completed psychosocial assessments when they began the study and at subsequent 6-month visits; psychosocial assessments were completed for 232 of 295 (79%) participants.
All study subjects were tested for inherited mutations in 12 genes that are associated with increased breast cancer risk via panel testing. Women with high-risk mutations who completed 5 years of the study protocol were offered continued screening.
This single-institution research shows bi-annual breast MRIs, radiology reader expertise, careful clinical decision making, and improved MRI technology at the University of Chicago can detect early-stage breast cancer more effectively than an annual MRI and mammogram. Other institutions with different cohorts of women may observe varying rates of success with biannual MRI screening. In addition, this study involved a relatively small sample size: only 295 women. Thus, this innovative screening approach needs to be further evaluated to refine and personalize breast cancer risk assessment and prevention.
In this study, biannual breast MRI accomplished the ultimate goal of breast cancer screening—detecting node-negative, invasive tumors smaller than 1 cm. Semiannual MRI performed especially well in BRCA1 mutation carriers who are at increased risk for the most aggressive subtype of breast cancer. Bi-annual MRI did not cause a significantly elevated state of depression or anxiety or a significant decline in mental health over time, regardless of cancer history or genetic mutation status. Finally, this single institution MRI protocol achieved recall rates lower than those considered acceptable for annual MRI or mammography.
Study co-author, Mary-Claire King, PhD said, "The central goal of our study was to understand the needs of the highest risk women. My concern is that mammography and MRI be used in ways that make sense given a woman's personal genetics. Women with mutations in BRCA1 or BRCA2 have very different needs for surveillance for breast disease than do women with no mutations in these genes. This is particularly true for healthy young women with mutations. It's truly critical to offer intensive surveillance to still-healthy women with BRCA1 or BRCA2 mutations."
Share your thoughts on this XRAYS article by taking our brief survey